

29/05/2026

The Deputy Manager
Corporate Relationship Department
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400001

Scrip Code: 544529

ISIN: INE15XJ01010

Dear Sir/Madam,

Sub: Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has prepared an Investor Presentation for dissemination to investors/analysts.

The Investor Presentation provides an overview of the Company's business operations and financial performance based on publicly available information and disclosures already made by the Company from time to time. The said presentation does not contain any unpublished price sensitive information.

In compliance with Regulation 46 of the SEBI (LODR) Regulations, 2015, the Investor Presentation will also be made available on the Company's website under the "Investor Relations" section.

A copy of the Investor Presentation is enclosed herewith for your records.

Kindly take the same on record.

Thanking you,

Yours faithfully

For Aptus Pharma Limited

Hathi Tejash
Maheshchandra

Digitally signed by Hathi
Tejash Maheshchandra
Date: 2026.05.29 13:11:58
+05'30'

Tejash Maheshchandra Hathi
Managing Director
DIN: 03151221

Encl.: Investor Presentation

**Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,
Ahmedabad, Gujarat – 382427, India**

**Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com
CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM**

INVESTOR PRESENTATION

 Aptus Pharma



Aptus Pharma Limited

Connecting.....Life



Disclaimer

This communication is being issued by Aptus Pharma Ltd. (“the Company”) for general information purposes only. The information contained herein is based on management’s current expectations and beliefs and is subject to change without notice. Certain statements in this document may be forward-looking in nature and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied.

This document does not constitute or form part of any offer, invitation, or recommendation to purchase, hold, or sell any securities of the Company, nor shall any part of it form the basis of or be relied upon in connection with any contract or investment decision.

The financial results referred to herein are prepared in accordance with applicable Indian Accounting Standards and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and are subject to audit / limited review by the statutory auditors of the Company.

Neither the Company nor its directors, officers, employees, or advisors accept any liability whatsoever for any loss or damage arising from the use of this information.

The Company undertakes no obligation to update any forward-looking statements or information contained herein to reflect subsequent events or circumstances, except as required under applicable law.

Company Overview

Aptus Pharma Ltd., established in 2010, is a fast-growing player in India's pharmaceutical sector, driven by a strong focus on brand building and market expansion. The company is engaged in developing and promoting high-quality pharmaceutical brands across diverse therapeutic segments, earning trust among healthcare professionals and consumers.



Operating on an asset-light model, Aptus partners with WHO-GMP certified manufacturers to ensure quality, scalability, and efficiency, enabling agile growth in competitive markets. With a growing presence across multiple states, the company has built a robust network of doctors, distributors, and healthcare professionals, supported by a dedicated field force.

Aptus offers a diversified portfolio of 250+ formulations spanning chronic, acute, and wellness segments. Its business is strategically structured across key verticals: the Rx Vertical, which drives core revenues through prescription-based therapies and strong doctor engagement; the OTC Vertical, focused on consumer healthcare and wellness products; and the Global Vertical, which expands international reach while contributing to revenue through exports and related service income. The company also operates its Orbit Division, a scalable, franchisee-led growth platform designed to accelerate market penetration, empower entrepreneurial partners, and extend the company's branded portfolio into high-potential and underpenetrated markets.

As a Public Limited Company listed on the BSE SME platform, Aptus Pharma Ltd. continues to strengthen its position with a vision of delivering accessible, affordable, and high-quality healthcare solutions while driving sustainable and scalable growth

Leader vision



Mr. Tejash Hathi
Managing Director

At Aptus Pharma Limited, our vision is to build a future where quality healthcare solutions are accessible, reliable, and driven by innovation. We aspire to be a globally trusted pharmaceutical organization, recognized for excellence, integrity, and sustainable growth.

Our focus is on continuously strengthening our capabilities, embracing innovation, and setting new benchmarks in pharmaceutical excellence. Through a commitment to quality and responsible progress, we aim to create lasting value for patients, healthcare professionals, partners, and communities.

With a future-oriented mindset, we are dedicated to shaping a healthier tomorrow—where growth is aligned with purpose, progress is guided by responsibility, and success is measured by the positive impact we create.

Driven by purpose. Defined by quality. Focused on the future.

Key USPs of APPL

- Diversified portfolio across pharma, Acute, Chronic, Urocare, Critical Care OTC, wellness, and personal care categories positions Aptus Pharma Limited as a dynamic and growth-oriented healthcare company.
- Aptus Pharma Limited operates an asset-light, marketing- and distribution-focused business model. Through outsourcing and loan licensing arrangements with WHO-GMP-certified contract manufacturers, the company conserves capital by avoiding heavy investments in manufacturing facilities. This strategic approach allows Aptus Pharma to redirect resources toward sales growth, brand building, product portfolio expansion, and the development of a strong nationwide supply chain.



Operational Milestone



250+

Pharmaceutical Formulations



15+

Therapeutic Segments



150+

Experts & Professionals Team
Across All Departments




2

Loan Licence Manufacturing Facility
9+ Contract Manufacturing facility tie-up
3 NABL Accredited Associate Lab



200+

distributors And
Sub-Distributors



50K+

Rx Per Day



BSE SME
Listed Company



Trusted By

10K+

Honourable Doctors



Our Leadership & Management



Mr. Tejash Maheshchandra Hathi

Managing Director and Promoter

Mr. Tejash Maheshchandra Hathi holds an MBA in Marketing and Management Accounting from Saurashtra University (2003) and is currently pursuing a Ph.D. in Management from Rai University, Ahmedabad.

He brings over two decades of rich experience in the pharmaceutical industry and has been associated with the Company since its inception in 2010. Initially serving as Director, he was appointed Managing Director effective January 17, 2024. In this leadership role, he is responsible for overseeing the Company's day-to-day operations and shaping its strategic direction.



Mr. Ghanshyam Vinubhai Pansuriya

Chief Executive Officer and Promoter

Mr. Ghanshyam Vinubhai Pansuriya holds a Bachelor of Science degree (2007) from Saurashtra University and a Diploma in Pharmacy (2019) from Sunrise University. With over 15 years of experience in the pharmaceutical industry, he has held key positions that have contributed to his deep domain expertise. He began his career as a Marketing Executive at Alkem Ulticare in 2008, followed by a role as a Business Development Executive at Panacea Biotech Ltd. in 2009. He later gained valuable experience at Macleod's Pharmaceuticals Ltd., where he further honed his skills in pharmaceutical sales and business development.



Mr. Kapil Hasmukhbhai Chandarana

Chief Financial Officer and Promoter

Mr. Kapil Hasmukhbhai Chandarana holds a Bachelor's degree in Social Work (BSW) from Saurashtra University (2017) and an MBA in Finance from Madhyanchal Professional University, Bhopal (2023).

He brings over 16 years of extensive experience in logistics and customs operations. From 2005 to 2021, he served as Zonal Manager at Velji Dosabhai & Sons Private Limited, where he developed strong operational and managerial expertise.



Mr. Nirav J. Pandya

Vice President-Pan-India Operations

Mr. Nirav J. Pandya is the Vice President of Aptus Pharma Limited, responsible for overseeing Pan-India operations. With a distinguished career spanning over 27 years in the pharmaceutical industry, he brings deep expertise in sales leadership, team development, and strategic business expansion.

He holds a Bachelor of Science degree in Chemistry from Navyug Science College, Gujarat University (1995-1998). Mr. Pandya began his career as a Medical Representative at Zydus Cadila Healthcare and went on to hold progressively senior roles at Glenmark Pharmaceuticals and J.B. Chemicals & Pharmaceuticals Ltd., advancing from Area Manager to Regional Sales Manager.

Our Leadership & Management



Mr. Riddhish Natwarlal Tanna

Non-Executive Director

Mr. Riddhish Natwarlal Tanna, aged 50 years, is the Non-Executive Director and one of the Promoters of the Company and also a homeopathic practitioner and healthcare management professional with experience in academic and administrative roles. He holds a Diploma in Homeopathic Medicine & Surgery (D.H.M.S.) from the Homeopathic Council of Homeopathic System of Medicine, Gujarat, an M.D. in Homeopathy from Sardar Patel University, and an MBA in Hospital Management from Sarvepalli Radhakrishnan University, Bhopal. He has also completed certifications in healthcare quality implementation from the National Board of Quality Promotion and the Health Sector Skill Council of India.



Mr. Chetan Shantilal Lalseta

Non-Executive Director

Mr. Chetan Shantilal Lalseta, aged 48 years, is the Non-Executive Director and one of the Promoters of the Company and also a Consultant Dermatologist, Venereologist, and Cosmetologist with over 20 years of experience by profession. He completed his M.B.B.S. in 2001 and M.D. (Skin & V.D.) in 2003 from Saurashtra University. He practices at Shraddha Hospital, Rajkot, and is a panel consultant at Wockhardt Hospital and Sterling Hospital. He also serves as a visiting faculty member at multispecialty hospitals in Rajkot.



Mr. Vikas Rambhai Jobanputra

Independent Director

Vikas Rambhai Jobanputra, aged 56 years, is the Independent Director of our Company. He holds a Diploma in Fabrication Technology from the Technical Examinations Board, Gujarat. He has over three decades of extensive experience in managing operations and business development within the machinery manufacturing sector. His expertise spans project and equipment sales, techno-commercial marketing, and the development of new markets to drive business excellence.



Sejal Harit Palan

Independent Director

Sejal Harit Palan, aged 42 years, is an Independent Director of our Company. She has been an Associate Member of the Institute of Company Secretaries of India (ICSI) since 2012 and has been in practice since September 2014 under her proprietorship firm Sejal Palan & Co., Practising Company Secretaries. She holds a Bachelor of Commerce degree from Bhawanipur Educational Society College, Kolkata; a Post Graduate Diploma in Business Management from Symbiosis Centre for Distance Learning, Pune; a Bachelor of Laws (LL.B.) from K.A. Pandhi Law College, Rajkot; and a Master of Laws (LL.M.) from Saurashtra University, Rajkot.

QUALITY PARAMETERS FOR EACH BATCH

At Aptus Pharma Ltd., every batch undergoes stringent quality evaluation to ensure safety, efficacy, and compliance with global standards.

- 1. Assay of Active Pharmaceutical Ingredients (API)**
- 2. Dissolution & Disintegration Profile**
- 3. Uniformity of Content (UOC)**
- 4. Related Substances Compliance**
- 5. Impurity Profiling**
- 6. Tablet/Capsule Hardness Test**
- 7. pH Level Evaluation**
- 8. Microbiological Analysis**
- 9. Friability Testing**
- 10. Karl Fischer (KF test)**
- 11. Diethylene glycol (DEG) and ethylene glycol (EG) Test**



QUALITY POLICY

At Aptus, we firmly believe that “Quality is a Habit, not an act.” Our quality assurance system spans the entire product lifecycle—from raw material sourcing to finished product delivery.

We implement stringent quality control measures using advanced analytical techniques such as HPLC (High-Performance Liquid Chromatography).

- 1. Assay and content uniformity**
- 2. Dissolution and disintegration studies**
- 3. Stability and friability testing**
- 4. Impurity and related substances analysis**

We strictly adhere to Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP), ensuring excellence in manufacturing and supply chain operations.

Our commitment is to deliver pharmaceutical products that are safe, effective, and of the highest quality standards.



Manufacturing Facilities



**Our loan licence
manufacturing facilities**

Facility No: 1



Aptus Pharma Limited

(WHO-cGMP Certified Unit)




AT:   29, Xcelon Industrial Park-1, Vasna-Chacharwadi,
Ahmedabad-382213 (Gujarat) INDIA.

Facility No: 2



Aptus Pharma Limited

(WHO-cGMP Certified Unit)

AT:    Plot No. 767/1, Vadsar-Motibhoyan Road, VIII,
Vadsar Tal. Kalol-382721, Dist. Gandhinagar, Gujarat, India.

**Our esteemed contract
manufacturers of our
brands**



**Our esteemed contract
manufacturers of our OTC
brands**



Core Values



Quality



Trustworthiness



Commitment



Hardwork

Divisions



Aptus Pharma
(Pioneer Division)



APTUS CD CARE
(Cardiac Diabetic Division)

APTUS WellCare
(Health And Personal Care Division)

APTUS Global
(Export Division)

APTUS Orbit
(Franchise Division)

Flagship Brands

Chilkul

Telbira

Timglo

Awards & Certifications

We are committed to maintaining the highest standards of quality, safety, and excellence in the pharmaceutical industry. Our achievements, awards, and certifications reflect our dedication to innovation, customer satisfaction, and regulatory compliance. With a strong focus on international quality standards, our manufacturing and operational processes are designed to ensure reliability, efficiency, and trust. These recognitions inspire us to continue delivering high-quality pharmaceutical solutions while strengthening our reputation as a dependable healthcare partner.



Business Process Flow

**Demand
Estimation of
Product**

**Selection of
Manufacturing
Facility**






**Issuance of
Purchase Order**

**Manufacturing
of Products**

**Quality
Approvals**

**Optimized supply
System powering final
sales growth**

Range Of Solutions



Leading Prescription Brands



Chilkul-20
Rabeprazole 20mg Tablets

Chilkul-E40
Esomeprazole 40mg Tablets

Chilkul-ED 40
Esomeprazole 40mg + Domperidone 30mg (SR) Capsules

Chilkul-DSR
Rabeprazole 20mg + Domperidone 30mg (SR) Capsules

Chilkul-RAFT
Each Sachet contains Sodium Alginate 250mg + Sodium Bicarbonate 133.5mg + Calcium Carbonate 80mg Suspension

Vomitus-MD
Mouth Dissolving Tablets
Ondansetron 4mg

Vonkul-10
Vonoprazan 10mg Tablets

Vonkul-20
Vonoprazan 20mg Tablets

Bactiklin 200
Cefpodoxime 200mg Tablets

Faxiking 200/400
Rifaximin 200mg / 400mg Tablets

The Terminator
Klaviking-625+
Amoxicillin 500mg + Clavulanic Acid 125mg + Lactic Acid Bacillus 60 Million Spores Tablets

Koltus-AB 200
Acebrophylline 200mg (SR) Tablets

Koltus-D
Each Sachet contains Dextromethorphan HBr 15mg + Chlorpheniramine Maleate 2mg + Phenylephrine 5mg Syrup

Koltus-PRO
Each Sachet contains Levocetirizine Fumarate 35.4mg (Eq. to Levocetirizine HCL 20mg) Suspension

Koltus-M
Montelukast 10mg + Levocetirizine 5mg Tablets

A complete Nutritional supplement
Nutritus
Multivitamin, Multimineral, Biotin With Grape Seed Extract Tablets

Nutritus DM
Methylcobalamin 1500mcg + Folic Acid 5mg + Pyridoxine 3mg + Vitamin D3 1000iu Tablets

Dolotus-SP
Aceclofenac 100mg + Paracetamol 325mg + Serratiopeptidase 15mg Tablets

Pgtus-Total
Pregabalin 75mg (SR) + Nerifityline 10mg + Methylcobalamin 1500mcg Bilayered Tablets

A Broad spectrum Antimicrobial
Zimking-200+
Cefixime 200mg + Lactic Acid Bacillus 2.5 Billion Spores Tablets

Aptifresh-MD
Mouth Dissolving Tablets
Clonazepam 0.5mg

Telbira-40
Telmisartan 40mg Tablets

Telbira-AM
Telmisartan 40mg + Amlodipine 5mg Tablets

Jugsi-100
Sitagliptin 100 mg Tablets

Jugempa-M
Empagliflozin 5mg + Metformin Hydrochloride 500mg 5/500 Tablet

Rozutus-Gold 20
Rosuvastatin 20mg + Aspirin 75mg + Clopidogrel 75mg Capsules

OTC & Wellness Brands



Key Milestones

● 2010

Incorporation of our company under the name "Aptus Pharma Private Limited".



● 2011 - 16

In 2011 Company formally launched with 2 headquarters and 11 products at a small scale, and grew by 2016 with a product line of 50+ and approx. 25% of state-level presence.



● 2016 - 20

The company has increased its product line in acute division as well as expanding its foot prints at the state level with an increase in acute therapy products. And make the company's foundation and fundamentals strong by introducing the system and process in all divisions.



● 2021 - 25

The Company strengthened its presence in two states with a portfolio of over 210 products across 11+ therapeutic segments. It appointed a Vice President for Domestic Sales & Marketing, launched three domestic divisions, entered the OTC and wellness segment, and shifted its operational headquarters from Rajkot to Ahmedabad to support national expansion. A centralized hi-tech depot in Ahmedabad and a strong sales and distribution network across Gujarat and West Bengal further reinforced its domestic market presence.



September, 2025

Get Listed on the BSE -SME platform



Key Highlights & Achievements (F.Y. 2025-26)



Revenue doubled to
₹4,670.81 lakh (+89.59% YoY)



EBITDA at
₹750.32 lakh (+57.73% YoY)



PAT at
₹461.99 lakh (+49.05% YoY)



Expanded portfolio to
250+ formulations



Strong presence across
Rx | OTC | Global | ORBIT verticals



Distribution network:
25,000+ retailers & 200+ distributors



Trusted by
10,000+ doctors



Asset-light model ensuring
scalability & efficiency



Listed on
BSE SME platform



Roadmap for pan-India
**expansion & global footprint
by 2030**


Performance



Year	2022-23	2023-24	2024-25	2025-26
Turnover	1,389.74	1,788.23	2,463.64	4,670.81


Performance

EBITDA



Year	2022-23	2023-24	2024-25	2025-26
EBITDA	57.46	149.29	475.70	750.32

Performance



Year	2022-23	2023-24	2024-25	2025-26
PAT	19.43	79.81	309.96	461.99

Expansion

Core Business Expansion

APPL will continue to scale its established divisions:



Aptus Pharma (Pioneer Division)

Core pharmaceutical formulations
across multiple therapies



APTUS CD CARE (Cardiac Diabetic Division)

Cardio-diabetic and chronic care
products

APTUS WellCare (Health And Personal Care Division)

Health, wellness, and personal
care products

APTUS Global (Export Division)

Overseas Market and export
related services oriented

These divisions will remain the backbone of the Company's growth.

Launch of New Divisions

To accelerate growth and address emerging therapeutic and market opportunities, APL plans to introduce the following new divisions in coming years:

APTUS Mindcare (Neuro-Psychiatric Division)

APL Mindcare will focus on neuro and psychiatric therapies, a fast-growing and high-prescription-continuity segment. This division is expected to strengthen the Company's presence in chronic and specialty therapies, offering long-term prescription stickiness and higher entry barriers.

APTUS Orbit (Franchise Division)

This division will operate on a franchise-based model, enabling rapid geographic expansion with lower capital deployment. The franchise model will be primarily used for penetrating new and underserved markets, especially in north-eastern, Assam and Seven Sisters belt .

Vertical Expansion Strategy

APPL plans to enter manufacturing through a wholly owned subsidiary:(cosmacutial and wellnes focused)

- Manufacturing limited to nutraceutical and cosmeceutical products
- Facility proposed at Ahmedabad
- Production to be used for:
 - Captive consumption for APL's domestic business
 - Export supply
 - B2B manufacturing for other pharmaceutical companies

This backward integration is expected to improve margins, ensure quality control, support exports.

Export Expansion – Global Footprint

APPL proposes to incorporate a wholly owned export subsidiary:

This entity will be responsible for all export operations. A dedicated Global Export Head will be appointed to oversee regulatory compliance, registrations, partnerships, and market development.

Target Export Markets:



• **Latin America:**
Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Peru



• **Africa:**
Middle Africa: Angola, Republic of Congo
East Africa: Kenya, Malawi, Somalia, Tanzania, Uganda



• **Asia:**
UAE, Malaysia, Myanmar, Cambodia, Vietnam, Bangladesh, Sri Lanka, Nepal (Nepal operations limited to cosmeceutical and nutraceutical products)



The export strategy aims to diversify revenue streams and establish APPL as an emerging global pharmaceutical and wellness player.

Product Portfolio Expansion

Currently, APPL markets approximately 250+ products across its existing divisions. Over the next three years, the Company plans to expand its product portfolio to approximately 500+ products, structured as follows:

- Pioneer Division: **250+ products including existing SKUs**
- Wellcare Division: **100+ products including existing SKUs**
- CD Care Division: **100+ products including existing SKUs**
- Mindcare Division: **50+**

The expanded product basket will enable deeper doctor engagement, improved therapy coverage, and higher prescription density.



Domestic Expansion

APPL's domestic expansion will follow a phased, structured approach, combining direct marketing and franchise models.

This roadmap is designed to ensure operational control while scaling nationally.

Zone	Status	Timeline
Gujarat	Strong Presence	Launched Since 2011
Rest of Maharashtra	Presence	Launched - May 2026
Goa	Proposed	To be Launched by July 2026
Mumbai	Proposed	To be Launched by Sep 2026
Rajasthan Chhatisgarh Madhya Pradesh	Proposed	To be Launched by June 2027
Andhra Pradesh Tamil Nadu Kerala Karnataka Telangana	Proposed	To be Launched by December 2027
Bihar	Proposed	To be Launched by April 2028
Uttar Pradesh	Proposed	To be Launched by September 2028
Rest India including Delhi	Proposed	To be Launched by March 2029
West Bengal	Presence	Since 2025
Odisha Assam North-Eastern states (7 Sister States)	Proposed	By March 2027 (Franchise Model) APTUS Orbit

VISION



Post-Expansion Group Structure and long term vision

Following the successful execution of the 3-year strategic plan, Aptus Pharma Limited (APPL) will operate through an integrated group structure.

Aptus Pharma Limited (Listed Entity) will maintain a strong nationwide presence, supported by subsidiaries focused on manufacturing, exports, and continuing its core business in both Rx and OTC segments.

This integrated structure is designed to support scalability, governance clarity, and focused management.

By the end of FY 2029, APL aims to evolve into:

- A PAN-India pharmaceutical brand
- A global exporter of pharma, nutraceutical, and cosmeceutical products
- A manufacturer with captive and B2B capabilities

The Company's strategy is built on **disciplined execution, capital efficiency, and long-term value creation for shareholders.**

BRAND PROMISE

"We committed to healthcare and healthcare professionals." Aptus Pharma pledges to uphold the highest standards in contributing to the well-being of individuals and supporting the healthcare community.



Events

CONFERENCE



TEAM ENGAGEMENT ACTIVITIES



Events

GIVING BACK TO SOCIETY



INVESTOR MEET



LISTING CEREMONY





Aptus Pharma Limited
Consolidating...Life

CORE VALUES Quality Trustworthiness Commitment Hardwork

APTUS PHARMA LIMITED DOURI ES REVENUE

Builds 250+ Product Portfolio and Accelerates Multi-Vertical Expansion.

Aptus Pharma Doubles Revenue, Builds 250+ Product Portfolio

Over the past few years, Aptus Pharma has demonstrated a strong performance with a consistent growth in revenue and a robust product portfolio. The company's revenue has doubled, and it has built a portfolio of over 250 products. This growth is attributed to the company's focus on research and development, and its commitment to quality and customer service. The company's revenue has grown from INR 100 Crores in 2018 to INR 200 Crores in 2021. The company's product portfolio has grown from 100 products in 2018 to 250 products in 2021. The company's revenue has grown by 100% and its product portfolio has grown by 150%.

BSE SME Listed Aptus Pharma Limited Doubles Revenue, Builds 250+ Product Portfolio, and Accelerates Multi-Vertical Expansion

Aptus Pharma Limited is a BSE SME listed company that has achieved significant milestones in its growth journey. The company's revenue has doubled, and it has built a portfolio of over 250 products. This growth is attributed to the company's focus on research and development, and its commitment to quality and customer service. The company's revenue has grown from INR 100 Crores in 2018 to INR 200 Crores in 2021. The company's product portfolio has grown from 100 products in 2018 to 250 products in 2021. The company's revenue has grown by 100% and its product portfolio has grown by 150%.

BSE SME Listed Aptus Pharma Limited Doubles Revenue

Aptus Pharma Limited is a BSE SME listed company that has achieved significant milestones in its growth journey. The company's revenue has doubled, and it has built a portfolio of over 250 products. This growth is attributed to the company's focus on research and development, and its commitment to quality and customer service. The company's revenue has grown from INR 100 Crores in 2018 to INR 200 Crores in 2021. The company's product portfolio has grown from 100 products in 2018 to 250 products in 2021. The company's revenue has grown by 100% and its product portfolio has grown by 150%.

BSE SME Listed Aptus Pharma Limited Builds 250+ Product Portfolio and Accelerates Multi-Vertical Expansion

Aptus Pharma Limited is a BSE SME listed company that has achieved significant milestones in its growth journey. The company's revenue has doubled, and it has built a portfolio of over 250 products. This growth is attributed to the company's focus on research and development, and its commitment to quality and customer service. The company's revenue has grown from INR 100 Crores in 2018 to INR 200 Crores in 2021. The company's product portfolio has grown from 100 products in 2018 to 250 products in 2021. The company's revenue has grown by 100% and its product portfolio has grown by 150%.

बीएसई लिस्टेड अप्टस फार्मा लि. ने 250+ प्रोडक्ट पोर्टफोलियो बनाया और मल्टी-वर्टिकल विस्तार को तेज किया

अप्टस फार्मा लि. एक बीएसई लिस्टेड कंपनी है जो अपने 250+ प्रोडक्ट पोर्टफोलियो और मल्टी-वर्टिकल विस्तार के लिए जानी जाती है। कंपनी का राजस्व दोगुना हो गया है, जो इस तेज वृद्धि का प्रमुख कारण है।

बीएसई लिस्टेड अप्टस फार्मा लि. ने 250+ प्रोडक्ट पोर्टफोलियो बनाया और मल्टी-वर्टिकल विस्तार को तेज किया

अप्टस फार्मा लि. एक बीएसई लिस्टेड कंपनी है जो अपने 250+ प्रोडक्ट पोर्टफोलियो और मल्टी-वर्टिकल विस्तार के लिए जानी जाती है। कंपनी का राजस्व दोगुना हो गया है, जो इस तेज वृद्धि का प्रमुख कारण है।



Aptus Pharma Limited
Consolidating...Life

CORE VALUES Quality Trustworthiness Commitment Hardwork

APTUS PHARMA LIMITED DOURI ES REVENUE

Builds 250+ Product Portfolio and Accelerates Multi-Vertical Expansion.

बीएसई लिस्टेड अप्टस फार्मा लि. ने 250+ प्रोडक्ट पोर्टफोलियो बनाया और मल्टी-वर्टिकल विस्तार को तेज किया

अप्टस फार्मा लि. एक बीएसई लिस्टेड कंपनी है जो अपने 250+ प्रोडक्ट पोर्टफोलियो और मल्टी-वर्टिकल विस्तार के लिए जानी जाती है। कंपनी का राजस्व दोगुना हो गया है, जो इस तेज वृद्धि का प्रमुख कारण है।

Aptus Pharma Limited doubles revenue

CHANGGARH: BSE SME Listed Aptus Pharma Limited Doubles Revenue, Builds 250+ Product Portfolio, and Accelerates Multi-Vertical Expansion. In a strong phase of growth and creation, Aptus Pharma Limited has delivered a standout performance with revenue doubling and a robust increase in its product portfolio. The company has evolved into a fast-growing pharmaceutical player focused on brand building, product expansion, and market penetration. BSE

नवभारत

एप्टस फार्मा का लाभ 49% बढ़ा

मुंबई, बीएसई लिस्टेड एप्टस फार्मा लिमिटेड ने वित्त वर्ष 2020-21 में अपने राजस्व को 49% और कुल लाभ को 405 कोड़ रुपये तक बढ़ाया है। 21 मार्च 2021 को समाप्त वित्त वर्ष में कंपनी ने 46.72 करोड़ के राजस्व का 4.62 करोड़ रुपये का शुद्ध लाभ बनाया, जबकि पिछले वित्त वर्ष में 31.45 करोड़ के शुद्ध लाभ हुआ था।

बीएसई लिस्टेड अप्टस फार्मा लि. ने 250+ प्रोडक्ट पोर्टफोलियो बनाया और मल्टी-वर्टिकल विस्तार को तेज किया

अप्टस फार्मा लि. एक बीएसई लिस्टेड कंपनी है जो अपने 250+ प्रोडक्ट पोर्टफोलियो और मल्टी-वर्टिकल विस्तार के लिए जानी जाती है। कंपनी का राजस्व दोगुना हो गया है, जो इस तेज वृद्धि का प्रमुख कारण है।

एप्टस फार्मा लि. ने 250+ प्रोडक्ट पोर्टफोलियो बनाया और मल्टी-वर्टिकल विस्तार को तेज किया

अप्टस फार्मा लि. एक बीएसई लिस्टेड कंपनी है जो अपने 250+ प्रोडक्ट पोर्टफोलियो और मल्टी-वर्टिकल विस्तार के लिए जानी जाती है। कंपनी का राजस्व दोगुना हो गया है, जो इस तेज वृद्धि का प्रमुख कारण है।

बीएसई लिस्टेड अप्टस फार्मा लि. ने 250+ प्रोडक्ट पोर्टफोलियो बनाया और मल्टी-वर्टिकल विस्तार को तेज किया

अप्टस फार्मा लि. एक बीएसई लिस्टेड कंपनी है जो अपने 250+ प्रोडक्ट पोर्टफोलियो और मल्टी-वर्टिकल विस्तार के लिए जानी जाती है। कंपनी का राजस्व दोगुना हो गया है, जो इस तेज वृद्धि का प्रमुख कारण है।

OUR DIVISIONS

Aptus Pharma (Power Division)
APTUS WellCare (Health and Personal Care Division)
APTUS Global (Export Division)

www.apтус-pharma.com | info@apтусpharma.com | export@apтусpharma.com

OUR DIVISIONS

Aptus Pharma (Power Division)
APTUS WellCare (Health and Personal Care Division)
APTUS Global (Export Division)

www.apтус-pharma.com | info@apтусpharma.com | export@apтусpharma.com



Aptus Pharma Limited
Coexisting...Life

CORE VALUES Quality Trustworthiness Commitment Hardwork

APTUS PHARMA LIMITED DOUBLES REVENUE

Builds 250+ Product Portfolio and Accelerates Multi-Vertical Expansion.

એપ્ટસ ફાર્મા લી.એ આવક બમણી કરી, 250+ પ્રોડક્ટ પોર્ટફોલિયો બનાવ્યો

મુંબઈ | વૃદ્ધિ અને અમલીકરણ મજબૂત તબક્કામાં, એપ્ટસ ફાર્મા લિમિટેડ આવક અબધી કરીને અને ગોળા નકલમાં મજબૂત વૃદ્ધિ સાથે કોરુપ્ટ પ્રકારેનું કાર્ય કર્યું છે. જે 35 અને કમ્પોઝીટી તકાલ અન્નને પ્રતિબિંબિત કરે છે. બીએસઈ એક્સએમઈ પોર્ટફોલિયો પર વિસ્તૃ એપ્ટસ ફાર્મા લિમિટેડ 2030 સુધીમાં સમાપ્ત અવસ્થામાં હાજરી પ્રદર્શન કરવા, વધુ સારા માર્કિટ અને નિયંત્રણ માટે તેની ડિવલપ્ડ કમ્પાઉન્ડો વિસ્તાર કરવા અને તેની નિવસ પહેલ દ્વારા વેધિક સત્તરે હાજરી અભાવ માટે સ્વપ્ન તે એવું સાથે તેની સ્થિતિ મજબૂત કરવાનું વધુ સાથે છે.

બીએસઈ એક્સએમઈ વિસ્તૃ એપ્ટસ ફાર્મા લી.એ આવક બમણી કરી

મુંબઈ | વૃદ્ધિ અને અમલીકરણ મજબૂત તબક્કામાં, એપ્ટસ ફાર્મા લિમિટેડ આવક અબધી કરીને અને ગોળા નકલમાં મજબૂત વૃદ્ધિ સાથે કોરુપ્ટ પ્રકારેનું કાર્ય કર્યું છે. જે 35 અને કમ્પોઝીટી તકાલ અન્નને પ્રતિબિંબિત કરે છે. બીએસઈ એક્સએમઈ પોર્ટફોલિયો પર વિસ્તૃ એપ્ટસ ફાર્મા લિમિટેડ 2030 સુધીમાં સમાપ્ત અવસ્થામાં હાજરી પ્રદર્શન કરવા, વધુ સારા માર્કિટ અને નિયંત્રણ માટે તેની ડિવલપ્ડ કમ્પાઉન્ડો વિસ્તાર કરવા અને તેની નિવસ પહેલ દ્વારા વેધિક સત્તરે હાજરી અભાવ માટે સ્વપ્ન તે એવું સાથે તેની સ્થિતિ મજબૂત કરવાનું વધુ સાથે છે.

એપ્ટસ ફાર્માની આવક અને નફામાં વૃદ્ધિ નોંધાઈ

વૃદ્ધિ સાથે સમતીકરણ મજબૂત તબક્કામાં, એપ્ટસ ફાર્મા લિમિટેડ આવક બમણી કરીને અને ગોળા નકલમાં મજબૂત વૃદ્ધિ સાથે કોરુપ્ટ પ્રકારેનું કાર્ય કર્યું છે. જે 35 અને કમ્પોઝીટી તકાલ અન્નને પ્રતિબિંબિત કરે છે. બીએસઈ એક્સએમઈ પોર્ટફોલિયો પર વિસ્તૃ એપ્ટસ ફાર્મા લિમિટેડ 2030 સુધીમાં સમાપ્ત અવસ્થામાં હાજરી પ્રદર્શન કરવા, વધુ સારા માર્કિટ અને નિયંત્રણ માટે તેની ડિવલપ્ડ કમ્પાઉન્ડો વિસ્તાર કરવા અને તેની નિવસ પહેલ દ્વારા વેધિક સત્તરે હાજરી અભાવ માટે સ્વપ્ન તે એવું સાથે તેની સ્થિતિ મજબૂત કરવાનું વધુ સાથે છે.

એપ્ટસ ફાર્માની આવક અને નફામાં વૃદ્ધિ નોંધાઈ

વૃદ્ધિ સાથે સમતીકરણ મજબૂત તબક્કામાં, એપ્ટસ ફાર્મા લિમિટેડ આવક બમણી કરીને અને ગોળા નકલમાં મજબૂત વૃદ્ધિ સાથે કોરુપ્ટ પ્રકારેનું કાર્ય કર્યું છે. જે 35 અને કમ્પોઝીટી તકાલ અન્નને પ્રતિબિંબિત કરે છે. બીએસઈ એક્સએમઈ પોર્ટફોલિયો પર વિસ્તૃ એપ્ટસ ફાર્મા લિમિટેડ 2030 સુધીમાં સમાપ્ત અવસ્થામાં હાજરી પ્રદર્શન કરવા, વધુ સારા માર્કિટ અને નિયંત્રણ માટે તેની ડિવલપ્ડ કમ્પાઉન્ડો વિસ્તાર કરવા અને તેની નિવસ પહેલ દ્વારા વેધિક સત્તરે હાજરી અભાવ માટે સ્વપ્ન તે એવું સાથે તેની સ્થિતિ મજબૂત કરવાનું વધુ સાથે છે.

એપ્ટસ ફાર્માની આવક અને નફામાં વૃદ્ધિ નોંધાઈ

વૃદ્ધિ સાથે સમતીકરણ મજબૂત તબક્કામાં, એપ્ટસ ફાર્મા લિમિટેડ આવક બમણી કરીને અને ગોળા નકલમાં મજબૂત વૃદ્ધિ સાથે કોરુપ્ટ પ્રકારેનું કાર્ય કર્યું છે. જે 35 અને કમ્પોઝીટી તકાલ અન્નને પ્રતિબિંબિત કરે છે. બીએસઈ એક્સએમઈ પોર્ટફોલિયો પર વિસ્તૃ એપ્ટસ ફાર્મા લિમિટેડ 2030 સુધીમાં સમાપ્ત અવસ્થામાં હાજરી પ્રદર્શન કરવા, વધુ સારા માર્કિટ અને નિયંત્રણ માટે તેની ડિવલપ્ડ કમ્પાઉન્ડો વિસ્તાર કરવા અને તેની નિવસ પહેલ દ્વારા વેધિક સત્તરે હાજરી અભાવ માટે સ્વપ્ન તે એવું સાથે તેની સ્થિતિ મજબૂત કરવાનું વધુ સાથે છે.

એપ્ટસ ફાર્માની આવક અને નફામાં વૃદ્ધિ નોંધાઈ

વૃદ્ધિ સાથે સમતીકરણ મજબૂત તબક્કામાં, એપ્ટસ ફાર્મા લિમિટેડ આવક બમણી કરીને અને ગોળા નકલમાં મજબૂત વૃદ્ધિ સાથે કોરુપ્ટ પ્રકારેનું કાર્ય કર્યું છે. જે 35 અને કમ્પોઝીટી તકાલ અન્નને પ્રતિબિંબિત કરે છે. બીએસઈ એક્સએમઈ પોર્ટફોલિયો પર વિસ્તૃ એપ્ટસ ફાર્મા લિમિટેડ 2030 સુધીમાં સમાપ્ત અવસ્થામાં હાજરી પ્રદર્શન કરવા, વધુ સારા માર્કિટ અને નિયંત્રણ માટે તેની ડિવલપ્ડ કમ્પાઉન્ડો વિસ્તાર કરવા અને તેની નિવસ પહેલ દ્વારા વેધિક સત્તરે હાજરી અભાવ માટે સ્વપ્ન તે એવું સાથે તેની સ્થિતિ મજબૂત કરવાનું વધુ સાથે છે.



Aptus Pharma Limited
Coexisting...Life

CORE VALUES Quality Trustworthiness Commitment Hardwork

APTUS PHARMA LIMITED ENTERS UROLOGY SEGMENT

Aptus Pharma Enters Fast-Growing Urology Segment

New Delhi, Aptus Pharma Limited announced a major strategic step in its business expansion, confirming its entry into the rapidly growing Urology therapy segment of the Indian pharmaceutical market. The move is poised to strengthen the company's specialty-care portfolio and is expected to become a key contributor to its future financial performance. This product line-up positions Aptus Pharma as a leader in the nation's fastest-growing chronic therapy segments, currently demonstrating an annual expansion rate of approximately 9-10%. The successful introduction and expansion of this new portfolio will be underpinned by the company's significant operational strengths, including:

Aptus Pharma announced its strategic entry into the Urology therapy segment

At the end of 2023, Aptus Pharma Limited announced its strategic entry into the Urology therapy segment. The company is launching a new portfolio of products in this segment, including: Sitodan range, Formidex range, Aluxer formulations. The introduction of these products is supported by the Company's strong field-sales force and established distribution network consisting of 150+ PLS distributors and sub-distributors across India. This new portfolio is expected to contribute significantly to the Company's future annual growth and profitability. The Urology market is one of the fastest-growing chronic therapy segments, currently demonstrating an annual expansion rate of approximately 9-10%. The successful introduction and expansion of this new portfolio will be underpinned by the company's significant operational strengths, including:

Expanding horizons

Aptus Pharma Limited has announced its strategic entry into the Urology therapy segment as part of its ongoing business expansion initiatives. The introduction of these products is supported by the company's strong field-sales force and established distribution network consisting of 150+ PLS distributors and sub-distributors across India. Commenting on this development, Tejash Hathi, the managing director of APL, states, "Our entry into the urology therapy segment further strengthens our specialty-care capabilities and positions the company for sustained growth in the coming years."

એપ્ટસ ફાર્માએ વિસ્તરણના ભાગરૂપે યુરોલોજી થેરાપી સેગ્મેન્ટમાં પ્રવેશ કર્યો

મુંબઈ | એપ્ટસ ફાર્મા લિમિટેડ વિસ્તૃ કરવાનું કાર્ય કર્યું છે. જે 35 અને કમ્પોઝીટી તકાલ અન્નને પ્રતિબિંબિત કરે છે. બીએસઈ એક્સએમઈ પોર્ટફોલિયો પર વિસ્તૃ એપ્ટસ ફાર્મા લિમિટેડ 2030 સુધીમાં સમાપ્ત અવસ્થામાં હાજરી પ્રદર્શન કરવા, વધુ સારા માર્કિટ અને નિયંત્રણ માટે તેની ડિવલપ્ડ કમ્પાઉન્ડો વિસ્તાર કરવા અને તેની નિવસ પહેલ દ્વારા વેધિક સત્તરે હાજરી અભાવ માટે સ્વપ્ન તે એવું સાથે તેની સ્થિતિ મજબૂત કરવાનું વધુ સાથે છે.



Aptus Pharma Limited
Connecting.....Life

Since 2011

CORE VALUES Quality Trustworthiness Commitment Hardwork

APTUS PHARMA EXPANDS OTC PRESENCE

अप्टस फार्मा ने गुजरात में ओटीसी प्रेजेंस का विस्तार

अप्टस फार्मा लिमिटेड, गुजरात में ओटीसी प्रेजेंस का विस्तार करने के लिए एक नए अभियान शुरू करेगी।

अप्टस फार्मा लिमिटेड, गुजरात में ओटीसी प्रेजेंस का विस्तार करने के लिए एक नए अभियान शुरू करेगी।

Aptus Pharma Expands OTC Presence in Gujarat

Ahmedabad, The expansion focuses on high-demand consumer categories, including face care, body and skin care, and hair care. The division will be driven by flagship brands such as Tingle, Kerova, and Shirovita, which are expected to deliver strong consumer traction across key markets. As part of its forward-looking strategy, Aptus Pharma Limited plans to further strengthen its footprint in the OTC and cosmeceutical segment. The company is preparing to broaden its product portfolio with new launches in hygiene care, pain relief, and oral care, along with upcoming SKUs such as Tingle Detox and Kerova Shea Moisturizer. To support this

Accelerating growth

Aptus Pharma expands OTC presence in Gujarat, strengthening cosmeceutical portfolio

Aptus Pharma Limited is a growing pharmaceutical company with a strong presence in the OTC and cosmeceutical segment, supported by a robust distribution network and dedicated sales force. The company continues to strengthen its presence in specialty and chronic therapy segments as part of its long-term strategic roadmap.

“Tijes Hathi, the managing director of Aptus Pharma Limited, stated: “The expansion of our OTC business across high-demand consumer categories strongly positions Aptus Pharma Limited to capture a larger share of Gujarat’s rapidly advancing OTC and personal care market.”

अप्टस फार्मा ने गुजरात में ओटीसी प्रेजेंस का विस्तार

अप्टस फार्मा लिमिटेड, गुजरात में ओटीसी प्रेजेंस का विस्तार करने के लिए एक नए अभियान शुरू करेगी।

अप्टस फार्मा लिमिटेड, गुजरात में ओटीसी प्रेजेंस का विस्तार करने के लिए एक नए अभियान शुरू करेगी।

अप्टस फार्मा ने गुजरात में ओटीसी प्रेजेंस का विस्तार

अप्टस फार्मा लिमिटेड, गुजरात में ओटीसी प्रेजेंस का विस्तार करने के लिए एक नए अभियान शुरू करेगी।

अप्टस फार्मा लिमिटेड, गुजरात में ओटीसी प्रेजेंस का विस्तार करने के लिए एक नए अभियान शुरू करेगी।

OUR DIVISIONS

Aptus Pharma
(Pharmaceutical Division)

APTUS CD CARE
(Cosmetics, Diagnostics, Devices)

APTUS WellCare
(Health And Personal Care Division)

APTUS Global
(Export Division)

www.apтус-pharma.com | info@apтусpharma.com | export@apтусpharma.com



Aptus Pharma Limited
Connecting.....Life

BOARD OF APTUS PHARMA LTD. ANNOUNCES 3:2 BONUS ISSUE

The Board of Aptus Pharma Limited, in their meeting dated March 24, 2026, has announced a bonus share issue in the ratio of 3:2, which shall further require Approval from its shareholders.

Impact - If the Bonus is approved by members

Shareholders will receive **3 additional shares for every 2 shares held**, increasing their total holdings without any extra investment.

The bonus issue reflects the company's strong financial position and confidence in its future growth prospects. It is also expected to enhance stock liquidity and attract wider investor participation.

Further details such as the record date and approval process are available under announcements at www.bseindia.com --> **Aptus Pharma Ltd.**

OUR DIVISIONS :

Aptus Pharma
(Pharmaceutical Division)

APTUS CD CARE
(Cosmetics, Diagnostics, Devices)

APTUS WellCare
(Health And Personal Care Division)

APTUS Global
(Export Division)



Aptus Pharma Limited
Connecting.....Life



APTUS PHARMA LIMITED EXPANDS INTO LIFE-SAVING INJECTABLES AND ICU CARE

We are proud to mark a significant milestone in our growth journey.

Following our recent expansion into OTC and Uro Care, Aptus Pharma Limited is now entering the **Life-Saving Injectables & ICU Care segment.**

This strategic step reflects our commitment to strengthening our portfolio in high-acuity therapeutic areas and addressing critical healthcare needs.

At Aptus Pharma Limited, we remain dedicated to advancing healthcare through quality, innovation, and responsibility.

OUR DIVISIONS :



APTUS WellCare
(Health And Personal Care Division)

APTUS Global
(Export Division)



Aptus Pharma Limited
Connecting.....Life

Since
2011

APTUS PHARMA STRENGTHENS BRAND PRESENCE AT RAJKOT HIRASAR AIRPORT



In a strategic brand-building initiative, Aptus Pharma has taken over the Baby Care Room at Rajkot Hirasar Airport to promote its upcoming baby care and OTC product portfolio. This initiative is aimed at enhancing brand visibility among travelers and families while creating strong awareness for the company's expanding healthcare range.

Scaling Trust Through

- Quality
- Trustworthiness
- Commitment
- Hardwork

The premium placement at one of Gujarat's growing airports is expected to provide significant mileage in strengthening customer trust, improving market reach, and establishing a stronger presence in the OTC and baby care segment.

રાજકોટ આંતરરાષ્ટ્રીય હવાઈ યાત્રા કેન્દ્ર RAJKOT INTERNATIONAL AIRPORT

OUR DIVISIONS



APTUS WellCare
(Health And Personal Care Division)

APTUS Global
(Export Division)



www.aplus-pharma.com | info@apluspharma.com | export@apluspharma.com

Aptus Pharma Limited
Connecting...Life

PROUDLY
FEATURED IN
**INDIA
Forbes**
February 6, 2026

Aptus Pharma Limited: Scaling Trust Through Quality, Affordability, and People-Centric Growth

Aptus Pharma Limited has achieved its 10th anniversary milestone by building exceptional company growth in quality, innovation, leadership, and trust. Beginning with a portfolio of four products, the company focused on simplifying its business before expanding its portfolio. Over time, Aptus Pharma has raised its profile as a multi-sect organization with strategic investments across.

Under this growing, aptus aims to do with more. The company adopted a focused approach, promoting ongoing initiatives. Aptus Pharma's leadership believes that its people growth is Aptus's growth. In terms of product, focus, expansion, patients, and mission.

Proven Strategy in Creating a World-Class Quality And Patient Care

The growth of Aptus Pharma Limited is closely linked to the success of its Founder and Managing Director, Mr. Rishi Maheshwari MD, who led a multi-decade battle in Patanjali, Unani, Ayurvedic discipline and regulatory (CDSCO, FDA, WHO) before he professionalized in 2010, as it grew with a proven set of 1000+ people building a management organization, to show its own in its operations level to gain further expansion. It's only after the first 1000+ people as a medical organization, focused operations in drug, equipment, R&D, services, distribution, supply and retail growth.

Through consistent operations and strong leadership management, the program was able to build its value. These operations shaped its organizational structure, to ensure a process and company delivery quality continues to provide more of its own expansion.

In 2011, the first 1000+ people, the multi-faceted Aptus Pharma Private Limited, began with limited resources, the company expanded steadily while valuing its own value. This foundation philosophy continues to influence the organizational culture, with its operations in long-term performance.

Qualities of the Organization
Quality management is Aptus Pharma's organization. Each product, customer, and quality checks before release introduction, ensuring consistency and safety across all products, with its ability and capacity. Through process and continuous research, innovation and service delivery.



Photo: Rishi

The company follows a balanced sector approach, the consistent customer, employee, and investor to key stakeholders. Leadership believes customer growth is possible only when the patient grows together. Supporting the company's business from a regulatory perspective to an emerging national presence.

Reliable Pricing with Patient Centricity
Aptus Pharma operates with a strong ecosystem of India's healthcare landscape, where a large number of its products belong to middle-income households. The company believes medicine pricing should remain reasonable, ensuring growth over our entire line of services.

Working across all businesses, People, Product, Production, and Pricing—the company operates collaboratively while ensuring its brand-building efforts. Aptus Pharma follows an open right model, focusing on partnerships rather than being a competitor.

By building up with established transactions across the sector, the company produces quality medicines at competitive prices. It provides evidence of its quality (1) on the customer's satisfaction.

A Strong Customer Relationship Experience
As the company's focus shifts to Aptus Pharma Limited, which is involved in various projects, companies across all sectors and industries, which is a key to long-term sustainability.

The company works with multiple stakeholders, the primary ones are customer, vendor, employee, customer, regulatory, and delivery customers. Over its entire portfolio of five products, the company has managed more than 200 products, with business growth by market demand and regulatory requirements.

Medical Device Development for Best Results
Aptus Pharma products are supported by continuous medical feedback. There is a strong focus on device, regulatory, and FDA approval to understand the specific needs and emerging trends. Over the years, the company has a strong focus on digital innovation, which supports the operational leadership and efficient work practices.

As it grows forward, Aptus Pharma India focuses on strengthening governance, operational discipline, and sustainable growth. While quality is its core, innovation is a guiding principle, and people are its strength. The company continues to build a sustainable pharmaceutical organization that is consistent, credible, and transparent across all sectors.



APTUS PHARMA LIMITED

Scaling Trust Through

- Quality
- Trustworthiness
- Commitment
- Hardwork

OUR DIVISIONS :

Aptus Pharma
(Pioneer Division)

APTUS CD-CARE
(Cardiac Diabetic Division)

APTUS WellCare
(Health And Personal Care Division)

APTUS Global
(Export Division)

Aptus Pharma Limited
Connecting...Life

Since 2011

CORE VALUES Quality Trustworthiness Commitment Hardwork

APTUS PHARMA IPO: CARE RATINGS CONFIRMS FUNDS USED AS PLANNED



Aptus Pharma Ltd received a clean report from CARE Ratings, confirming its entire ₹13.02 crore IPO proceeds were used exactly as disclosed. The report, submitted to BSE, shows no deviation in how funds were allocated to capital expenditure, working capital, general corporate purposes, and offer expenses. This assures investors of the company's commitment to its IPO promises.

Aptus Pharma
(Pioneer Division)

APTUS CD-CARE
(Cardiac Diabetic Division)

APTUS WellCare
(Health And Personal Care Division)

APTUS Global
(Export Division)



A COMPANY OF THE NEXT DECADE

From its humble beginning with four products to its current position as a listed pharmaceutical company, Aptus Pharma Limited stands as a testament to disciplined growth and strategic foresight.

As the Indian healthcare market continues to expand, Aptus Pharma is positioning itself confidently not just as a participant in the industry, but as a company of the next decade.



Scaling Trust Through

- Quality
- Trustworthiness
- Commitment
- Hardwork



OUR DIVISIONS



www.aplus-pharma.com | info@apluspharma.com | export@apluspharma.com



Aptus Pharma Limited
Connecting.....Life

Proud Moment for Aptus Pharma Limited!



Aptus Pharma Limited has been recognized by **News 18 Group** as the **Fastest Growing Ethical Pharma Company**.
The award was presented by
Hon'ble Deputy CM of Gujarat, Harsh Sanghavi Sir

Mr. Kapil Chandarana (CEO) and **Mr. Mahipal Zala (Dy. RSM)** accepted the honour on behalf of the company.
A proud achievement reflecting our commitment to ethical growth and healthcare excellence.

OUR DIVISIONS :



Indian Pharma Industry Landscape



The industry, currently valued at US\$55 billion, ranks third in the world by volume and 14th by value among pharmaceutical producers globally while dominance in generics and vaccines manufacturing being the pivotal part of the growth

Indian Pharma Industry is further estimated to grow to achieve an impressive value of US\$450 billion between 2025 and 2047 with continued focus on moving up the value chain

India is the source of 60,000 generic brands in >60 therapeutic categories

India's Pharma Market

India's cost-sensitive market continues to favor high-volume, lower-cost products, with generics dominating the therapeutic landscape

The MAT (moving avg Turnover) for the Indian Pharma Market between Aug'24 and July'25 increased by 7.4% achieving a total turnover of >US\$ 26 Billion led by chronic therapies

Cardiac, gastro-intestinal, anti-infectives and diabetic segments were the major growth contributors—where Cardiac and diabetes contributing ~25%

Indian Pharma Industry Growth Drivers



Growing Population

India's growing population provides a larger consumer base for pharmaceutical products, driving demand.



Low-cost Manufacturing Expertise

India's proficiency in cost-effective end-to-end manufacturing processes enables competitive pricing of pharmaceutical products, both domestically and globally.



Lifestyle Changes

Shifts in demographics and lifestyle patterns, such as an aging population and increasing prevalence of chronic diseases, lead to higher consumption of medications, particularly chronic medications.



Improving Affordability

Rising per capita incomes contribute to improved affordability of healthcare and pharmaceuticals, making them more accessible to a broader segment of the population.



Govt Support and Initiatives

Various government schemes and incentives, such as the Production Linked Incentive (PLI) scheme, bolster the pharmaceutical industry, encouraging investment and growth.



Modern Medicines Access

Efforts to enhance healthcare infrastructure and distribution networks are expanding access to modern and innovative medicines across the country.



www.aptus-pharma.com | info@aptuspharma.com | export@aptuspharma.com